CriticalHMG-CoA reductase inhibitor (statin)×Second-generation systemic triazole antifungal
Updated · Methodology
Mechanism
The liver enzyme CYP3A4 clears lovastatin (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and posaconazole strongly inhibits this enzyme (posaconazole SmPC, European Medicines Agency, EMA). Itraconazole 200 mg daily raised lovastatin exposure (area under the curve, AUC) more than 36-fold. According to the US Food and Drug Administration (FDA) lovastatin label, this result may also reflect the effect of posaconazole. CYP3A4 also clears simvastatin, and posaconazole oral suspension 100 or 200 mg once daily raised simvastatin AUC about 10-fold (posaconazole FDA label). High lovastatin levels raise the risk of muscle damage (myopathy) and muscle breakdown (rhabdomyolysis) (posaconazole and lovastatin SmPCs, EMA and AEMPS).
Symptoms
Myopathy causes muscle pain, tenderness or weakness, with creatine kinase (CK) above ten times the upper limit of normal (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In rhabdomyolysis, myoglobin from damaged muscle passes into the urine and can cause acute kidney failure, rarely fatal (lovastatin SmPC, AEMPS). Warning signs are unexplained muscle pain, tenderness or weakness, especially with malaise or fever (lovastatin label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated in the posaconazole summary of product characteristics (SmPC) of the European Medicines Agency (EMA), in the US Food and Drug Administration (FDA) posaconazole label and in the lovastatin FDA label. The contraindication covers all forms of posaconazole (posaconazole FDA label). Under the lovastatin SmPC of the Spanish Agency of Medicines and Medical Devices (AEMPS), strong CYP3A4 inhibitors are contraindicated with lovastatin, and posaconazole is a strong CYP3A4 inhibitor according to its own SmPC (posaconazole SmPC, EMA). If posaconazole is needed, stop lovastatin for the whole course of posaconazole (posaconazole SmPC, EMA; lovastatin FDA label). Atorvastatin and simvastatin are also contraindicated with posaconazole (posaconazole SmPC, EMA; posaconazole FDA label). Warn the patient which medicines must not be taken with lovastatin, and ask them to report unexplained muscle pain, tenderness or weakness at once (lovastatin FDA label). If the patient has already taken both drugs and develops muscle pain, weakness or cramps, measure creatine kinase (CK). Stop lovastatin if CK is above 5 times the upper limit of normal or myopathy is suspected (lovastatin SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Noxafil (posaconazole) prescribing information (2026)– FDA, DailyMed, Noxafil (Merck Sharp & Dohme), setid b073b082-7b57-4423-8c06-4fd4263d6f84, versión 56, revisión 02/2026, secciones 4.2, 4.3, 4.4, 4.5, 5.2 y 7.2
- EMA: Ficha técnica: Posaconazol (EU/1/05/320), sección 4.3 (2026)– EMA, Noxafil (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 105320002, consultada 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Lovastatina (nº registro 63360), sección 4.3 (2023)– AEMPS, CIMA, nº registro 63360 (Lovastatina Cinfa 20 mg, Laboratorios Cinfa), documento 05/2023 (texto revisado 05/2023), secciones 4.3, 4.4 y 4.5; texto idéntico en Lovastatina Cinfa 40 mg (nº registro 63359)
- FDA: Lovastatin Tablets USP (lovastatin) prescribing information (2026)– FDA, DailyMed setid df7ddf4f-d569-431e-81f1-9129d7043150 (Lupin Pharmaceuticals), revisión 05/2026 (versión 17), Clinical Pharmacology (tabla I), Contraindications, Warnings (Myopathy/Rhabdomyolysis) y Precautions